August 25, 1969

Dr. Wilma Harrison
Geigy Pharmaceuticals
Ardsley, New York

Dear Dr. Harrison:

Our initial trials with GP 41,299 have progressed well. In 15 trials in normal volunteers, we have used dosages of 25 to 200 mg. The observation period of EEG and behavior has been 1 1/2 hours. We have also obtained the subject's reports of the succeeding 16-24 hours.

We have observed behavioral effects of sedation, drowsiness and lassitude at dosages over 100 mg. These symptoms persist for many hours, the subjects reporting sleeping late the next day.

The EEG changes are defined as increased theta and some delta; reduced beta activity; and a decrease in amplitudes.

These preliminary data are insufficient to classify GP 41,299 but do provide the basis for the second phase study as outlined in our protocol. Before undertaking this study, however, I am anxious to check a few records at a longer time period (4 hours). As soon as these trials are completed, I will send you a revised part 2 of the protocol.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp